Orthogon Therapeutics Closes Oversubscribed $5.2M Financing to Advance First Oral Therapy for BK Polyomavirus

Contributed by: Business Wire

Images

Ultrastructural representation of the BK polyomavirus capsid, featuring 72 pentamers that form its distinct icosahedral symmetry. (Graphic: Business Wire)
Ultrastructural representation of the BK polyomavirus capsid, featuring 72 pentamers that form its distinct icosahedral symmetry. (Graphic: Business Wire)
Business Wire embedded0

Tags

Venture Capital
Stem Cells
Biotechnology
Pharmaceutical
General Health
Health
Professional Services
Other Health
Orthogon Therapeutics

More Like This

SpikImm Announces the Signature of an Exclusive License Option and Collaboration Agreement With SATT Conectus for the Development of a Prophylactic Treatment Against the BK Virus, Causing Severe Complications in Transplant Patients

GlobeNewswire associated0

4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy

PR Newswire associated0

YGION Biomedical announces €15 Million Series A Financing to develop Individualized Cancer Immunotherapies

Business Wire logo

Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

PR Newswire associated0

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

Business Wire logo

Novotech Releases Comprehensive Report on Oncolytic Virus Therapy

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options